United States Patent 8,679,533: Pramipexole Extended-Release Patent Scope, Expiration, and Competitive Landscape
U.S. Patent No. 8,679,533 protects once-daily oral sustained-release pramipexole compositions built around a starch and hydrophilic-polymer matrix. Its central coverage is not limited to a particular tablet recipe. Claim 1 combines composition ingredients, quantitative ranges, dissolution or absorption performance, once-daily dosing, and bioavailability equivalence to immediate-release pramipexole.
The patent is commercially relevant to Mirapex ER and other once-daily pramipexole extended-release products. The strongest infringement risk concerns tablets containing pramipexole dihydrochloride monohydrate dispersed through a starch/polymer matrix that produces delayed release and a pharmacokinetic profile comparable to three-times-daily immediate-release treatment.
What does U.S. Patent 8,679,533 cover?
U.S. Patent 8,679,533 covers an orally deliverable, once-daily, sustained-release pramipexole composition. The patent was issued on March 25, 2014. The assignee is Boehringer Ingelheim International GmbH, and the patent belongs to the pramipexole extended-release formulation family.[1]
The independent composition claim requires all of the following:
| Required element |
Claim 1 requirement |
| Active ingredient |
About 0.1 to about 10 mg pramipexole dihydrochloride monohydrate |
| Matrix excipients |
Starch at about 25% to about 75% by weight |
| Release-controlling excipient |
Hydrophilic polymer at about 20% to about 70% by weight |
| Physical arrangement |
Pramipexole dispersed in the starch and hydrophilic polymer |
| Dosage frequency |
Once daily |
| Dose architecture |
Full daily dose in a single dose unit |
| Release mechanism |
Hydrophilic polymer provides sustained release |
| Performance |
Specified in vitro dissolution profile or in vivo absorption profile |
| Bioavailability |
Substantially equivalent to an equal daily dose of immediate-release pramipexole administered three times daily |
The claim therefore operates as a combination claim. A product that contains pramipexole and a hydrophilic polymer but lacks the required starch range, dosage configuration, or release performance would not fall within the literal scope of claim 1.
How should the claim language be construed?
Claim 1 contains several limitations that materially narrow its scope.
Ingredient and concentration limitations
The composition must contain:
- Pramipexole dihydrochloride monohydrate in an amount of approximately 0.1 to 10 mg.
- Starch in an amount of approximately 25% to 75% by weight.
- Hydrophilic polymer in an amount of approximately 20% to 70% by weight.
The dependent claims narrow these ranges further. Claims 24 and 25 require starch concentrations of approximately 40% to 70% and 45% to 65%, respectively. Claims 26 through 28 require hydrophilic-polymer concentrations ranging from approximately 30% to 60%, 35% to 60%, or 35% to 50%.
The use of “about” creates tolerance around the numerical endpoints. The permissible range is fact-dependent and may be assessed against the patent specification, industry measurement practices, prosecution history, and the accused product’s actual composition. A competitor should not assume that a formulation just outside a stated range is automatically outside the claim.
Matrix-dispersion limitation
Pramipexole must be dispersed in the starch and hydrophilic polymer. This language is narrower than a formulation that merely contains starch and polymer as separate excipients.
The patent is directed to a matrix system in which the polymer controls release. A formulation using a membrane-coated pellet, osmotic pump, multiparticulate system, or a different release mechanism may present a stronger non-infringement position if the active ingredient is not dispersed in the claimed matrix. The doctrine of equivalents could still create risk if the alternative performs substantially the same function in substantially the same way to achieve substantially the same result.[2]
Once-daily and single-unit limitations
Claim 1 requires the full daily dose to be contained in a single dose unit. Claim 14 further specifies discrete dosage units, and claim 29 specifies a tablet.
A product administered twice daily, even if each unit uses the same matrix technology, would not literally satisfy the once-daily limitation. A product requiring two tablets to deliver the full daily dose may also raise a claim-construction issue because claim 1 requires the full daily dose in “a single dose unit.”
Functional release limitations
Claim 1 is satisfied by at least one of two performance alternatives:
- An in vitro release profile in which no more than approximately 20% dissolves within two hours under the specified USP24 conditions; or
- An in vivo absorption profile in which the time to reach 20% mean absorption exceeds approximately two hours and/or the time to reach 40% mean absorption exceeds approximately four hours.
The “or” structure is important. The patentee does not need to establish both alternatives if one is satisfied. Claims 2 through 6 add increasingly slow dissolution requirements:
| Claim |
Additional dissolution limitation |
| 2 |
No more than approximately 12% dissolved within one hour |
| 3 |
At least approximately four hours to reach 50% dissolution |
| 4 |
At least approximately six hours to reach 50% dissolution |
| 5 |
At least approximately eight hours to reach 50% dissolution |
| 6 |
At least approximately 12 hours to reach 50% dissolution |
The test conditions are material. The patent specifies USP24 Apparatus 1, a 100 rpm spindle speed, 0.05M phosphate buffer at pH 6.8, and 37°C. Results generated under a different apparatus, agitation speed, pH, buffer, or temperature may not establish literal satisfaction of the claimed dissolution limitation.
What do the dependent claims add?
The dependent claims create several distinct protection layers.
Pharmacokinetic claims
Claims 7 through 13 protect pharmacokinetic characteristics rather than only the formulation’s ingredients.
Relevant thresholds include:
- At least approximately five or six hours to reach 40% mean absorption.
- Cmax no greater than approximately 0.3 ng/mL after a 0.375 mg dose.
- Tmax of at least approximately six or eight hours.
- A steady-state fluctuation ratio no greater than that of the immediate-release reference regimen.
These claims may be difficult to assess without clinical pharmacokinetic data. They can, however, create infringement exposure even where the accused manufacturer does not disclose a complete formulation composition. An ANDA applicant’s bioequivalence data, dissolution data, and regulatory submissions may become relevant evidence.
Dose claims
Claims 15 through 23 cover dosage-unit amounts and specified strengths:
- Approximately 0.2 to 6 mg per unit.
- Approximately 0.3 to 5 mg per unit.
- 0.375 mg.
- 0.5 mg.
- 0.75 mg.
- 1.0 mg.
- 1.5 mg.
- 3.0 mg.
- 4.5 mg.
These dose claims align closely with the strength architecture used for pramipexole treatment. A product using one of the recited strengths may face additional dependent-claim exposure if it also satisfies the matrix and performance limitations of claim 1.
Dosage-form claims
Claim 29 is directed to a tablet. Claim 14 covers discrete dosage units more generally. A capsule, multiparticulate unit, or other oral unit may fall within claim 14 but outside claim 29, depending on its structure.
Which claims are likely to be strongest in enforcement?
Claim 1 is the principal commercial claim because it captures the core product architecture. Its breadth comes from the alternative dissolution and absorption tests, but it also contains numerous limitations that must be proven cumulatively.
Claims 2 through 6 are narrower but potentially more useful where a product has a particularly slow dissolution profile. Claims 10 through 13 may provide additional coverage if the accused product’s clinical or regulatory data show the required Cmax, Tmax, or fluctuation profile.
Claim 31 is a method-of-treatment claim for administering the claimed composition to a Parkinson’s disease patient not more than once daily. It can be relevant to marketed-product activity, but direct infringement generally requires an act of administration. In ANDA litigation, the proposed labeling and intended use are central to the analysis.[3]
What patent expiration date applies to U.S. Patent 8,679,533?
The patent’s base term is generally calculated from the earliest effective nonprovisional U.S. filing date for the relevant family, subject to patent-term adjustment, patent-term extension, terminal disclaimers, and other statutory rules.[4]
The pramipexole extended-release family traces back to an early-2000s priority period. On that basis, the unadjusted 20-year term would fall around the end of 2022. The enforceable expiration date requires review of the patent’s front-page patent-term adjustment, any terminal disclaimer, and the applicable family prosecution history.
The commercially relevant date should therefore be stated in two parts:
| Term component |
Assessment |
| Base statutory term |
Approximately 20 years from the earliest effective nonprovisional filing |
| Patent-term adjustment |
Must be taken from the issued patent record |
| Patent-term extension |
No extension should be assumed without an applicable regulatory order |
| Terminal disclaimer |
Must be checked against related patents |
| Practical expiry |
Determined from the issued patent and USPTO term data, not the grant date alone |
The grant date of March 25, 2014 is not the expiration date. Patent expiration cannot be calculated by adding 20 years to the issue date.
What is the Orange Book status of U.S. Patent 8,679,533?
The FDA Orange Book identifies patents submitted by NDA holders for approved drug products and identifies whether those patents are listed for the relevant NDA.[5] An issued patent can be legally enforceable without being listed in the Orange Book, while an Orange Book-listed patent can create an ANDA certification and litigation pathway.
For pramipexole extended-release products, the relevant regulatory product is Mirapex ER, marketed by Boehringer Ingelheim. The Orange Book analysis should distinguish among:
- Drug-substance patents.
- Formulation patents.
- Method-of-use patents.
- Patents listed for Mirapex ER.
- Patents listed for immediate-release Mirapex.
- Patents that have expired or been delisted.
- Patents with remaining enforceable term.
The claim set supplied for U.S. 8,679,533 is directed primarily to formulation and treatment use. It does not claim pramipexole as a chemical entity. Its Orange Book significance, if listed, would therefore arise from the extended-release dosage form and once-daily Parkinson’s disease treatment method.
What Paragraph IV challenges could target this patent?
An ANDA applicant seeking approval for generic pramipexole extended-release tablets could address an Orange Book-listed patent through one of four certifications:
- Paragraph I: no patent information has been submitted.
- Paragraph II: the patent has expired.
- Paragraph III: approval will be delayed until patent expiration.
- Paragraph IV: the patent is invalid, unenforceable, or will not be infringed.[6]
For this patent, a Paragraph IV strategy would likely focus on several issues.
Non-infringement arguments
A generic applicant could argue that its product:
- Does not contain starch within the claimed range.
- Uses a non-hydrophilic release-controlling system.
- Does not disperse pramipexole in the claimed matrix.
- Requires more than one unit for the full daily dose.
- Does not satisfy the specified dissolution profile.
- Does not satisfy the claimed pharmacokinetic profile.
- Uses a formulation that releases the active ingredient through a different mechanism.
Invalidity arguments
Potential invalidity theories could include:
- Anticipation by earlier sustained-release pramipexole or dopamine-agonist formulations.
- Obviousness based on matrix-tablet technology, starch excipients, hydrophilic polymers, and known once-daily pramipexole pharmacology.
- Lack of written description for the full scope of the numerical and pharmacokinetic ranges.
- Lack of enablement across the full combination of excipient ratios, strengths, release rates, and bioavailability requirements.
- Indefiniteness involving terms such as “about,” “substantially equivalent,” “not substantially greater,” and “standard dissolution test.”
The Supreme Court and Federal Circuit have treated pharmaceutical formulation patents under the ordinary anticipation, obviousness, enablement, written-description, and claim-construction standards. The commercial importance of the drug does not alter those tests.[7]
What generic entry risks exist?
Generic entry risk depends on three separate dates:
- Regulatory exclusivity expiration.
- Orange Book patent expiration or successful patent challenge.
- The earliest launch date permitted by any litigation settlement.
A formulation patent can delay generic entry even after new chemical entity exclusivity has expired. Conversely, an early patent expiration does not guarantee immediate generic approval if the ANDA remains incomplete or other listed patents remain in force.
The most credible entry scenarios are:
| Scenario |
Commercial result |
| Patent survives and no settlement permits early launch |
Generic launch delayed until enforceable patent expiry |
| Paragraph IV litigation ends in a generic victory |
Approval and launch may proceed after applicable regulatory conditions |
| Settlement provides a licensed early-entry date |
Entry occurs on the negotiated date |
| Product design avoids all claim limitations |
Approval may proceed without infringing this patent |
| Patent term has expired but other patents remain |
Entry remains blocked by the remaining patent estate |
How strong is the patent estate for once-daily pramipexole?
The patent estate is strongest against conventional hydrophilic-matrix tablets that use high starch and polymer loading and are designed to mimic the pharmacokinetic profile of Mirapex ER.
Its principal strengths are:
- Multiple independent technical requirements in the core claim.
- Alternative in vitro and in vivo performance routes.
- Dependent claims covering clinically relevant strengths.
- Pharmacokinetic claims that can be tested through regulatory data.
- A method-of-treatment claim tied to once-daily Parkinson’s therapy.
Its principal weaknesses are:
- The claim requires a specific excipient architecture.
- The dissolution test is highly protocol-dependent.
- The pharmacokinetic limitations may complicate infringement proof.
- The broad “about” ranges invite claim-construction disputes.
- Prior-art formulation patents may challenge obviousness.
- Patent-term value is limited by the family’s early priority period.
What manufacturing and formulation barriers does the patent create?
The patent does not prevent all generic pramipexole extended-release products. It targets a particular platform.
A competitor may reduce risk by changing one or more of the following:
- The release-control polymer.
- The starch level.
- The physical arrangement of pramipexole within the dosage form.
- The use of a coating or osmotic system instead of a matrix.
- The dose-unit configuration.
- The dissolution profile.
- The dosing schedule.
- The pharmacokinetic target.
Those changes may create new development and regulatory burdens. A noninfringing formulation still must demonstrate pharmaceutical equivalence, bioequivalence, stability, content uniformity, manufacturing consistency, and acceptable dissolution performance under FDA requirements.[8]
What licensing deals or settlements affect this patent?
No licensing agreement or settlement should be attributed to U.S. Patent 8,679,533 without a transaction document, court docket, consent judgment, or regulatory filing expressly identifying the patent.
Pramipexole extended-release litigation may involve related family members rather than this patent alone. A settlement referring to one patent does not necessarily grant rights under every continuation, divisional, or related formulation patent. The operative documents must be reviewed for:
- Patent numbers covered.
- Authorized product scope.
- Entry date.
- Manufacturing restrictions.
- Supply terms.
- No-challenge clauses.
- Geographic limitations.
- Acceleration or forfeiture provisions.
How does this patent compare with immediate-release pramipexole patents?
| Issue |
U.S. 8,679,533 |
Immediate-release pramipexole protection |
| Primary subject |
Sustained-release composition |
Drug substance, immediate-release formulation, or use |
| Dosing |
Once daily |
Commonly multiple daily doses |
| Key technology |
Starch/hydrophilic-polymer matrix |
Immediate-release dosage form or active ingredient |
| Proof of infringement |
Composition plus dissolution or PK performance |
Composition, strength, or treatment use |
| Commercial product |
Mirapex ER-type product |
Mirapex immediate-release product |
| Generic design-around |
Change matrix architecture or release mechanism |
More limited if claims focus on active ingredient or use |
The patent is a formulation patent, not a basic pramipexole molecule patent. Its value depends on the continued commercial use of the claimed extended-release architecture.
Key Takeaways
- U.S. Patent 8,679,533 covers once-daily pramipexole sustained-release compositions using a starch/hydrophilic-polymer matrix.
- Claim 1 requires the active ingredient, excipient ranges, matrix dispersion, single-unit daily dosing, and specified dissolution or absorption performance.
- Claims 2 through 6 strengthen protection through slower dissolution thresholds.
- Claims 7 through 13 add pharmacokinetic protection involving absorption, Cmax, Tmax, and fluctuation ratio.
- Claims 15 through 23 cover commercially relevant pramipexole strengths.
- Claim 31 covers once-daily administration for Parkinson’s disease.
- The patent’s base term traces to an early-2000s filing period; the exact enforceable expiration date depends on USPTO term adjustment and related-record analysis.
- Generic risk is highest for hydrophilic-matrix tablets using substantial starch and polymer loading.
- A coating-based, osmotic, multiparticulate, or otherwise non-matrix formulation may provide a design-around path, subject to equivalents and regulatory requirements.
- Orange Book listing, Paragraph IV exposure, litigation, and settlement rights must be assessed patent-by-patent within the Mirapex ER family.
FAQs
Does U.S. Patent 8,679,533 cover all pramipexole extended-release products?
No. It covers products satisfying the specific starch, hydrophilic-polymer, matrix-dispersion, once-daily, dosage-unit, and release or pharmacokinetic limitations.
Can a generic avoid the patent by using a different hydrophilic polymer?
Potentially, but changing the polymer alone may not be sufficient. The analysis must consider the claim’s functional release limitations and the doctrine of equivalents.
Does the patent cover a capsule containing multiple extended-release pellets?
Claim 14 may raise issues for discrete dosage units, but claim 29 is directed to a tablet. Coverage depends on whether the capsule satisfies the broader limitations of claim 1 and the structure of the pellets.
Is a Paragraph II certification available after the patent’s nominal term?
Yes, if the patent has expired under the legally applicable expiration date. The relevant date must account for patent-term adjustment, terminal disclaimers, and any extension.
Can the FDA approve a generic before patent expiration?
FDA approval and commercial marketing are separate issues. A generic may receive approval subject to patent certification rules, but commercial launch may remain restricted by litigation, injunction, settlement, or other listed patents.
References
-
U.S. Patent No. 8,679,533. (2014). Sustained release pharmaceutical composition comprising pramipexole. United States Patent and Trademark Office.
-
Warner-Jenkinson Co. v. Hilton Davis Chemical Co., 520 U.S. 17 (1997).
-
Eli Lilly & Co. v. Teva Parenteral Medicines, Inc., 8 F.4th 1332 (Fed. Cir. 2021).
-
35 U.S.C. §§ 154, 156.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.
-
21 U.S.C. § 355(j)(2)(A)(vii).
-
KSR International Co. v. Teleflex Inc., 550 U.S. 398 (2007); Amgen Inc. v. Sanofi, 598 U.S. 594 (2023).
-
U.S. Food and Drug Administration. (2003). Guidance for industry: Bioavailability and bioequivalence studies for orally administered drug products. FDA.
